What question did this study set out to answer?

March 13, 2026Open Access

Correction: Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis

Key Points

To evaluate the efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer.
Conducted a multi-center analysis
Compared outcomes between radiotherapy (RT) group and non-radiotherapy (Non-RT) group
Analyzed overall survival (OS) and progression-free survival (PFS) rates after propensity score matching (PSM)
One-year OS rates were 80.4% in the RT group compared to 62.2% in the Non-RT group
Two-year OS rates were 50.9% in the RT group compared to 34.1% in the Non-RT group
PFS was significantly longer after PSM in the RT group (12.7 months) compared to the Non-RT group (6.5 months), with HR=0.47 and p<0.001

Abstract

"The one-year and two-year OS rates were 80.4% and 50.9%, respectively, in RT group, compared to 62.2% and 34.1%, respectively, in Non-RT group." The PFS data after PSM was incorrectly copied as OS data. A correction has been made to the section Results, Survival outcomes, Paragraph 3: "After PSM, significant improvements in PFS(Figure3C,12.7months vs 6.5months, HR= 0.47, 95%CI:0.39-0.56, p<0.001)" The original version of this article has been updated.

KI fragen

Bookmark

View Full Paper